Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Vanessa E Gonzalez"'
Autor:
Julie K. Jadlowsky, Rachel Leskowitz, Stephen McKenna, Jayashree Karar, Yujie Ma, Anlan Dai, Gabriela Plesa, Fang Chen, Kathleen Alexander, Jennifer Petrella, Nan Gong, Wei-Ting Hwang, Olivia Farrelly, Julie Barber-Rotenberg, Shannon Christensen, Vanessa E. Gonzalez, Anne Chew, Joseph A. Fraietta, Carl H. June
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 32, Iss 1, Pp 101186- (2024)
The use of lentiviral vectors in cell and gene therapy is steadily increasing, both in commercial and investigational therapies. Although existing data increasingly support the usefulness and safety of clinical-grade lentiviral vectors used in cell m
Externí odkaz:
https://doaj.org/article/7bc0c17d5d0e4617bc7ee7d437b08ef4
Autor:
Alfred L. Garfall, Adam D. Cohen, Sandra P. Susanibar-Adaniya, Wei-Ting Hwang, Dan T. Vogl, Adam J. Waxman, Simon F. Lacey, Vanessa E. Gonzalez, Joseph A. Fraietta, Minnal Gupta, Irina Kulikovskaya, Lifeng Tian, Fang Chen, Natalka Koterba, Robert L. Bartoszek, Margaret Patchin, Rong Xu, Gabriela Plesa, Don L. Siegel, Andrea Brennan, Anne Marie Nelson, Regina Ferthio, Angela Cosey, Kim-Marie Shea, Rachel Leskowitz, Megan Four, Wesley V. Wilson, Fei Miao, Eric Lancaster, Beatriz M. Carreno, Gerald P. Linette, Elizabeth O. Hexner, Regina M. Young, Dexiu Bu, Keith G. Mansfield, Jennifer L. Brogdon, Carl H. June, Michael C. Milone, Edward A. Stadtmauer
Publikováno v:
Blood Cancer Discovery. 4:118-133
We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) patients responding to third- or later-line therapy (phase A, N = 10) or high-r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af15a4e58dc3d2eade0573800002170e
https://doi.org/10.1158/2643-3230.bcd-22-0074
https://doi.org/10.1158/2643-3230.bcd-22-0074
Autor:
Edward A. Stadtmauer, Michael C. Milone, Carl H. June, Jennifer L. Brogdon, Keith G. Mansfield, Dexiu Bu, Regina M. Young, Elizabeth O. Hexner, Gerald P. Linette, Beatriz M. Carreno, Eric Lancaster, Fei Miao, Wesley V. Wilson, Megan Four, Rachel Leskowitz, Kim-Marie Shea, Angela Cosey, Regina Ferthio, Anne Marie Nelson, Andrea Brennan, Don L. Siegel, Gabriela Plesa, Rong Xu, Margaret Patchin, Robert L. Bartoszek, Natalka Koterba, Fang Chen, Lifeng Tian, Irina Kulikovskaya, Minnal Gupta, Joseph A. Fraietta, Vanessa E. Gonzalez, Simon F. Lacey, Adam J. Waxman, Dan T. Vogl, Wei-Ting Hwang, Sandra P. Susanibar-Adaniya, Adam D. Cohen, Alfred L. Garfall
Supplemental tables: (1) Subject characteristics. (2) Cytogenetic profiles and high-risk features. (3) Prior treatment exposures and refractoriness. (4) CAR T cell product characteristics. (5) Products that did not meet target dose. (6) Adverse event
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a41bd0d88d5d4c7b561e5825c554cb6
https://doi.org/10.1158/2643-3230.22546220
https://doi.org/10.1158/2643-3230.22546220
Autor:
Edward A. Stadtmauer, Michael C. Milone, Carl H. June, Jennifer L. Brogdon, Keith G. Mansfield, Dexiu Bu, Regina M. Young, Elizabeth O. Hexner, Gerald P. Linette, Beatriz M. Carreno, Eric Lancaster, Fei Miao, Wesley V. Wilson, Megan Four, Rachel Leskowitz, Kim-Marie Shea, Angela Cosey, Regina Ferthio, Anne Marie Nelson, Andrea Brennan, Don L. Siegel, Gabriela Plesa, Rong Xu, Margaret Patchin, Robert L. Bartoszek, Natalka Koterba, Fang Chen, Lifeng Tian, Irina Kulikovskaya, Minnal Gupta, Joseph A. Fraietta, Vanessa E. Gonzalez, Simon F. Lacey, Adam J. Waxman, Dan T. Vogl, Wei-Ting Hwang, Sandra P. Susanibar-Adaniya, Adam D. Cohen, Alfred L. Garfall
We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) patients responding to third- or later-line therapy (phase A, N = 10) or high-r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80421cf85e910d57e6c55056f662dc98
https://doi.org/10.1158/2643-3230.c.6551123.v1
https://doi.org/10.1158/2643-3230.c.6551123.v1
Autor:
Tara C Mitchell, Robert H Vonderheide, Carl H June, Gabriela Plesa, Simon F Lacey, Irina Kulikovskaya, Vanessa E Gonzalez, Andrea Lynne Brennan, Gerald P Linette, E. John Wherry, Amy Marshall, Karen Dengel, Lester Lledo, Joan Gilmore, Joanne Shea, Amanda Cervini, Tina Matlawski, Julia Tchou, Paul Zhang, Lynn M. Schuchter, Ravi K Amaravadi, Robert Orlowski, Xiaowei Xu, Alexander C. Huang, Payal D Shah
Supplementary Figure 1. : Representative immunohistochemical staining for Subject 74 with metastatic melanoma; lymph node biopsy. Panel A: pS6 staining prior to infusion; Panel B: pS6 staining at post-infusion biopsy; Panel C: Ki-67 staining prior to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::231510cf468ded7c965e54cfc035befb
https://doi.org/10.1158/2767-9764.22535386.v1
https://doi.org/10.1158/2767-9764.22535386.v1
Autor:
Tara C Mitchell, Robert H Vonderheide, Carl H June, Gabriela Plesa, Simon F Lacey, Irina Kulikovskaya, Vanessa E Gonzalez, Andrea Lynne Brennan, Gerald P Linette, E. John Wherry, Amy Marshall, Karen Dengel, Lester Lledo, Joan Gilmore, Joanne Shea, Amanda Cervini, Tina Matlawski, Julia Tchou, Paul Zhang, Lynn M. Schuchter, Ravi K Amaravadi, Robert Orlowski, Xiaowei Xu, Alexander C. Huang, Payal D Shah
Supplementary Figure 2: Representative immunohistochemical staining for Subject 27 with metastatic triple-negative breast cancer; lymph node biopsy. Panel A shows CD8 staining prior to infusion and Panel B shows CD8 staining at the time of post-infus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::129c00eb78c481393aacb977d0f1d338
https://doi.org/10.1158/2767-9764.22535383
https://doi.org/10.1158/2767-9764.22535383
Autor:
Tara C Mitchell, Robert H Vonderheide, Carl H June, Gabriela Plesa, Simon F Lacey, Irina Kulikovskaya, Vanessa E Gonzalez, Andrea Lynne Brennan, Gerald P Linette, E. John Wherry, Amy Marshall, Karen Dengel, Lester Lledo, Joan Gilmore, Joanne Shea, Amanda Cervini, Tina Matlawski, Julia Tchou, Paul Zhang, Lynn M. Schuchter, Ravi K Amaravadi, Robert Orlowski, Xiaowei Xu, Alexander C. Huang, Payal D Shah
Purpose: Treatments are limited for metastatic melanoma (MM) and triple-negative breast cancer (mTNBC). This pilot phase I trial (NCT03060356) examined the safety and feasibility of intravenous RNA- electroporated chimeric antigen receptor (CAR) T ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb461f29152df1117010a2204b876486
https://doi.org/10.1158/2767-9764.c.6547846.v1
https://doi.org/10.1158/2767-9764.c.6547846.v1
Autor:
Stephan A. Grupp, David L. Porter, Carl H. June, Bruce L. Levine, Gerald Wertheim, Farzana Nazimuddin, Jason C. White, Stefan Rose-John, Zhaohui Zheng, Susan R. Rheingold, Colleen Callahan, Richard Aplenc, Robert A. Berg, Julie C. Fitzgerald, Scott L. Weiss, David M. Barrett, Jeffrey Finklestein, Fang Chen, Vanessa E. Gonzalez, Edward Pequignot, Noelle Frey, Shannon L. Maude, J. Joseph Melenhorst, Pamela A. Shaw, Simon F. Lacey, David T. Teachey
Supplementary methods, statistical methods, results, tables, and figures. Supplementary Table 1. CRS grading system. Supplementary Table 2. Samples collected and time points on the trials. Supplementary Table 3. HLH diagnostic criteria. Supplementary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b25964fa4b6a8e0a19d4230c9511d15
https://doi.org/10.1158/2159-8290.22532237
https://doi.org/10.1158/2159-8290.22532237
Autor:
Adam Waxman, Vanessa E. Gonzalez, J. Joseph Melenhorst, Lifeng Tian, Regina M. Young, Bruce L. Levine, Alfred L. Garfall, Gabriela Plesa, Michael C. Milone, Adam D. Cohen, Edward A. Stadtmauer, Dan T. Vogl, Simon F. Lacey, Carl H. June, Luca Bernabei
Publikováno v:
British Journal of Haematology. 193:851-855
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a30ad1a2adcd87a7b54a04f8314c3440
https://doi.org/10.1111/bjh.17397
https://doi.org/10.1111/bjh.17397
Autor:
Simon F. Lacey, Caroline Diorio, Edward M. Behrens, David M. Barrett, David L. Porter, Fang Chen, Jenny Bush, Bruce L. Levine, Alena Orlenko, Edward Pequignot, J. Joseph Melenhorst, Jason H. Moore, Natalka Koterba, Pamela A. Shaw, Richard Aplenc, Donglan Zhang, Michele Paessler, David T. Teachey, Vanessa E. Gonzalez, Don L. Siegel, Hamid Bassiri, Stephan A. Grupp, Megan M. Davis, Nuala J. Meyer, Scott L. Weiss, Amanda M. DiNofia, Shannon L. Maude, Carl H. June
Publikováno v:
Blood Adv
Chimeric antigen receptor (CAR) T-cells directed against CD19 have drastically altered outcomes for children with relapsed and refractory acute lymphoblastic leukemia (r/r ALL). Pediatric patients with r/r ALL treated with CAR-T are at increased risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9305269a592995d1690ebfa89bd814dc
https://doi.org/10.1182/bloodadvances.2020002592
https://doi.org/10.1182/bloodadvances.2020002592